» Articles » PMID: 31781124

Pattern Recognition Receptors in Multiple Sclerosis and Its Animal Models

Overview
Journal Front Immunol
Date 2019 Nov 30
PMID 31781124
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Pattern recognition receptors (PRRs) coordinate the innate immune response and have a significant role in the development of multiple sclerosis (MS). Accumulating evidence has identified both pathogenic and protective functions of PRR signaling in MS and its animal model, experimental autoimmune encephalomyelitis (EAE). Additionally, evidence for PRR signaling in non-immune cells and PRR responses to host-derived endogenous ligands has also revealed new pathways controlling the development of CNS autoimmunity. Many PRRs remain uncharacterized in MS and EAE, and understanding the distinct triggers and functions of PRR signaling in CNS autoimmunity requires further investigation. In this brief review, we discuss the diverse pathogenic and protective functions of PRRs in MS and EAE, and highlight major avenues for future research.

Citing Articles

Microglial Mayhem NLRP3 Inflammasome's Role in Multiple Sclerosis Pathology.

Fan H, Fu Q, Du G, Qin L, Shi X, Wang D CNS Neurosci Ther. 2024; 30(12):e70135.

PMID: 39690733 PMC: 11652677. DOI: 10.1111/cns.70135.


Brain alarm by self-extracellular nucleic acids: from neuroinflammation to neurodegeneration.

Kunze R, Fischer S, Marti H, Preissner K J Biomed Sci. 2023; 30(1):64.

PMID: 37550658 PMC: 10405513. DOI: 10.1186/s12929-023-00954-y.


Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis.

Zhao X, Jacob C Int J Mol Sci. 2023; 24(7).

PMID: 37047344 PMC: 10093908. DOI: 10.3390/ijms24076373.


New Insights into Risk Genes and Their Candidates in Multiple Sclerosis.

Shirai R, Yamauchi J Neurol Int. 2023; 15(1):24-39.

PMID: 36648967 PMC: 9844300. DOI: 10.3390/neurolint15010003.


RNA polymerase III and antiviral innate immune response.

Jarrous N, Rouvinski A Transcription. 2021; 12(1):1-11.

PMID: 33622180 PMC: 8172158. DOI: 10.1080/21541264.2021.1890915.


References
1.
Khan N, Kuo A, Brockman D, Cooper M, Smith M . Pharmacological inhibition of the NLRP3 inflammasome as a potential target for multiple sclerosis induced central neuropathic pain. Inflammopharmacology. 2017; 26(1):77-86. DOI: 10.1007/s10787-017-0401-9. View

2.
Inoue M, Chen P, Siecinski S, Li Q, Liu C, Steinman L . An interferon-β-resistant and NLRP3 inflammasome-independent subtype of EAE with neuronal damage. Nat Neurosci. 2016; 19(12):1599-1609. PMC: 5482232. DOI: 10.1038/nn.4421. View

3.
Shaw P, Lukens J, Burns S, Chi H, McGargill M, Kanneganti T . Cutting edge: critical role for PYCARD/ASC in the development of experimental autoimmune encephalomyelitis. J Immunol. 2010; 184(9):4610-4. PMC: 3001131. DOI: 10.4049/jimmunol.1000217. View

4.
Lukens J, Gurung P, Shaw P, Barr M, Zaki M, Brown S . The NLRP12 Sensor Negatively Regulates Autoinflammatory Disease by Modulating Interleukin-4 Production in T Cells. Immunity. 2015; 42(4):654-64. PMC: 4412374. DOI: 10.1016/j.immuni.2015.03.006. View

5.
Soares J, Oliveira E, Pontillo A . Variants in NLRP3 and NLRC4 inflammasome associate with susceptibility and severity of multiple sclerosis. Mult Scler Relat Disord. 2019; 29:26-34. DOI: 10.1016/j.msard.2019.01.023. View